In very high-risk ASCVD, use a LDL-C thresh-old of 70 mg/dL (1.8 mmol/L) to consider addition of nonstatins to statin therapy. Very high-risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions. In very high-risk ASCVD patients, it is reasonable to add ezetimibe
Cholesterol Management: ACC/AHA Updates Guideline - AAFP
2019年5月1日 · Based on high-quality evidence from randomized controlled trials (RCTs), high-intensity statin therapy should be instituted with a goal of lowering LDL-C levels by 50% or more in patients...
The 2018 Cholesterol Guideline is a full revision of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
Before initiating therapy for treatment of elevated blood cholesterol, doctors and their patients should consider these items. Calculate risk. Use the 2018 Prevention Guidelines Tool CV Risk Calculator. Assess lifestyle modifications. Review lifestyle habits (see inside panel) and emphasize a heart-healthy lifestyle.
In patients with clinical atherosclerotic cardiovascular disease (ASCVD), reduce low-density lipoprotein cholesterol (LDL-C) with high-intensity statin therapy or maximally tolerated statin therapy. In very high-risk ASCVD, use an LDL-C threshold of 70 mg/dL (1.8 mmol/L) to consider addition of non-statins to statin therapy.
Patients with extremely high LDL-C (190 mg/dL or more) or other conditions that can increase their ASCVD risk, and those who have been diagnosed with cardiovascular disease, need immediate intervention with high-intensity statins to manage their …
Cholesterol Guideline Hub - Journal of the American College of …
The purpose of the 2018 ACC/AHA Blood Cholesterol guideline is to address the practical management of patients with high blood cholesterol and related disorders.
The New 2018 Cholesterol Guidelines | Circulation - AHA/ASA …
2018年11月10日 · For the very high-risk patient with ASCVD and LDL-C ≥70 mg/dL despite maximal statin therapy, ezetimibe is the preferred initial agent (Class IIa; Level of Evidence B), and PCSK9 inhibitors (Class IIa; Level of Evidence A) are a reasonable option only if the patient is already prescribed statin and ezetimibe (Class I; Level of Evidence B).
Guideline Hub | Blood Cholesterol - American College of Cardiology
2018年11月10日 · Understanding the 2018 Cholesterol Guideline. Use these for critical decision making at the point-of-care. Increase patient knowledge and motivation with these resources.
2018 Guideline on the Management of Blood Cholesterol
2018年11月10日 · Scott Grundy, MD, PhD, chair of the writing group, announces the publication of the 2018 Guideline on the Management of Blood Cholesterol and describes the some of the changes in this update. The 2018 cholesterol guideline addresses the practical management of patients with high blood cholesterol and related disorders.